RxDoctor Payments Data

Yen Hui Huang

Cardiovascular Disease · Tucson, AZNPI 1164696779

Payments from drug & device makers

$1,136in general payments, 2019–2025

Across 27 payments — averaging $42.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$395
  • Johnson & Johnson$234
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$216
  • Astellas Pharma US Inc$130
  • Cleerly, Inc.$63
  • Esperion Therapeutics, Inc.$29
  • plus $70 from 4 others

What the payments were for

  • Food & beverage$1,03791%
  • Education$999%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,136 in reported general payments places this provider in the 30th percentile of 423 cardiovascular disease providers in Arizona.

See all cardiovascular disease providers in Arizona

Medicare billing

Part B allowed, 2024
$107,200
Medicare patients
1,011
Services billed
2,185

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban234$195,459
XareltoRivaroxaban131$101,216
EntrestoSacubitril/Valsartan114$95,827
JardianceEmpagliflozin62$56,688
FarxigaDapagliflozin Propanediol28$21,412
Repatha SureclickEvolocumab21$13,774
Praluent PenAlirocumab12$5,457
Ezetimibe189$4,806
Atorvastatin Calcium804$4,707
Metoprolol Succinate353$3,537
Rosuvastatin Calcium337$3,188
Carvedilol537$2,938
Potassium Chloride118$1,806
Hydralazine Hcl124$1,618
Losartan Potassium254$1,235

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$234$101,216131 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 423 cardiovascular disease providers in Arizona.

Other cardiovascular disease in Tucson

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →